DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Reisa Sperling - 3 “ - 2 ” Sperling - 2 Johnson - 2 Brigham - 2 Julie Steenhuysen - 2 Caroline Humer - 2 APOE4 - 1
Top related locs:
United States U.S Alzheimer’s Spain Santa Barcelona Wisconsin Boston , Massachusetts
Top related orgs:
Brigham - 2 National Institutes of Health - 2 Thomson - 2 CNN - 1 Nature - 1 National Alzheimer’s Coordinating - 1 Neurology - 1 Hospital de - 1

Search resuls for: "Reisa Sperling"


5 mentions found


☆ Genes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers say
  + stars: | 2024-05-06 | by ( Brenda Goodman | ) edition.cnn.com   time to read: +10 min
Among people diagnosed with Alzheimer’s, researchers recognize familial forms of the disease and sporadic cases. This shifting appreciation of inherited risk, researchers say, is due to a better understanding of the role of a fourth gene that carries the blueprints to make a lipid-carrying protein called apolipoprotein E, known as APOE. One known as APOE2 is thought to be protective against the development of Alzheimer’s disease. They also compared people with two copies of APOE4 to people with other inherited forms of the disease — early-onset autosomal dominant Alzheimer’s disease (ADAD) and Down syndrome-associated Alzheimer’s disease (DSAD). Gene testing isn’t currently recommendedIt is also likely to change how people who carry the APOE4 gene are diagnosed and treated.
Persons: APOE4, ”, Dr, Juan Fortea, Sant, Fortea, Charles Bernick, Bernick, Alzheimer’s wasn’t, isn’t, they’re, ” Fortea, Sanjay Gupta, Reisa Sperling, “, ” Sperling, ” Dr, Sterling Johnson, Johnson Organizations: CNN, Nature, National Alzheimer’s Coordinating, Neurology, Hospital de, Cleveland Clinic Lou, Brain Health, CNN Health, Alzheimer’s Research, Brigham, Women’s, Alzheimer’s, University of Wisconsin Locations: Alzheimer’s, Spain, United States, Santa, Barcelona, Wisconsin
☆ Researchers return to Alzheimer's vaccines, buoyed by recent drug success
  + stars: | 2023-11-20 | by ( Julie Steenhuysen | ) www.reuters.com   time to read: +6 min
The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. Dr. Reisa Sperling, an Alzheimer's researcher at Mass General Brigham in Boston, said she believes vaccines will play an important role as researchers look to prevent Alzheimer's. She is considering vaccines for her next study in asymptomatic people with Alzheimer's proteins in their blood, but not enough to register on brain scans. Alzheimer's vaccines are still in the early stages and will require large, years-long trials to show they work. Generating a strong immune response is critical for such vaccines, which would typically be given to older individuals with weaker immune systems, he said.
Persons: Brian Snyder, Eli Lilly's, Reisa Sperling, Brigham, “, ” Sperling, Walter Koroshetz, Mei Mei Hu, Vaxxinity, Hu, Michael Rafii, Rafii, Andrea Pfiefer, Johnson, Prothena, Gene Kinney, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: Alzheimer Research, Brigham, Women's, REUTERS, Rights, U.S . Food, Drug Administration, Mass, National Institutes of Health, UB, University of Southern, Johnson, Bristol Myers Squibb, Thomson Locations: Boston , Massachusetts, U.S, Boston, Taiwan, University of Southern California
☆ Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks
  + stars: | 2023-07-31 | by ( Julie Steenhuysen | ) www.reuters.com   time to read: +11 min
The company told Reuters that 49% of Black volunteers did not meet the trial's amyloid threshold requirements compared to 22% for whites and 55% for Hispanics. "Is it because MCI (mild cognitive impairment) or early dementia type-symptoms in Blacks are caused by other reasons more so than Alzheimer's?" In 96 dementia trials from 2000-2017, diverse populations only made up around 11% of enrollment, according to a 2018 study. Among Black people who died of Alzheimer's, their dementia was more likely to result from multiple causes, such as vascular disease. "Is it that it's not Alzheimer's disease?
Persons: Barrington, Vickie Riley, Charlie, Harriet Shaffer, Barrington Riley, –, Eli Lilly, Lilly, Crystal Glover, Eisai, Ivan Cheung, Cheung, Shobha, Biogen, Mark Mintun, Alzheimer's, Dr Lisa Barnes, Barnes, Joshua Grill, we're, Reisa Sperling, Brigham, Julie Steenhuysen, Caroline Humer, Suzanne Goldenberg, Daniel Flynn Organizations: Emory University Brain Health, Americans, Reuters, Prospective Black, Rush, Disease Research, and Drug Administration, FDA, Black, MCI, National Institutes of Health, Rush Center, University of California, Women's Hospital, Thomson Locations: Atlanta , Georgia, U.S, Chicago, Tokyo, Irvine, United States
☆ Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression
  + stars: | 2023-03-09 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +3 min
Eli Lilly on Wednesday said it will halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow disease progression. The study enrolled more than 1,000 seniors who had normal memory and thinking function, but showed signs of brain plaque that is associated with Alzheimer's. Lilly said it did not have that data because donanemab cleared brain plaque quickly in many patients. "We remain confident in the of potential donanemab as a new treatment for people with early symptomatic Alzheimer's disease," Skovronsky said. The FDA approved Eisai's and Biogen's early Alzheimer's treatment Leqembi on an expedited basis in January.
☆ Rare success for Alzheimer's research unlocks hope for future therapies
  + stars: | 2022-11-29 | by ( Julie Steenhuysen | ) www.reuters.com   time to read: +6 min
Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. Lecanemab’s success rests on years of research into the causes of Alzheimer’s as well as advances in measuring amyloid deposits through brain scans and spinal fluids. At least 16 treatments are being tested in clinical trials, with results expected over the next three years, according to a Reuters review of the clinicaltrials.gov registry. The drugmaker has been largely absent from the Alzheimer's space after the high-profile failure of its drug verubecestat five years ago. But several antibody therapies from Lilly, Biogen and AbbVie(ABBV.N) that were designed to slow the rate of tau accumulations failed outright last year.
0 next >>
Total: 5